drugset / Trial / NCT00782002
Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if IMC-18F1 is safe for patients, and also to determine the best dose of IMC-18F1 to give to patients.
Timeline
- Start
- 2006-07
- Primary completion
- 2009-03
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Icrucumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Icrucumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Icrucumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Icrucumab | Monoclonal antibody | 12 mg/kg | Intravenous |
| Subject | Icrucumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Icrucumab | Monoclonal antibody | 20 mg/kg | Intravenous |